The estimated Net Worth of Gordon Sangster is at least $1.03 million dollars as of 20 March 2019. Gordon Sangster owns over 80,000 units of Codexis stock worth over $476,257 and over the last 10 years Gordon sold CDXS stock worth over $551,213.
Gordon has made over 5 trades of the Codexis stock since 2018, according to the Form 4 filled with the SEC. Most recently Gordon exercised 80,000 units of CDXS stock worth $300,000 on 20 March 2019.
The largest trade Gordon's ever made was exercising 80,000 units of Codexis stock on 20 March 2019 worth over $300,000. On average, Gordon trades about 14,341 units every 16 days since 2014. As of 20 March 2019 Gordon still owns at least 174,453 units of Codexis stock.
You can see the complete history of Gordon Sangster stock trades at the bottom of the page.
Gordon's mailing address filed with the SEC is C/O CODEXIS, INC., 200 PENOBSCOT DRIVE, REDWOOD CITY, CA, 94063.
Over the last 15 years, insiders at Codexis have traded over $34,923,852 worth of Codexis stock and bought 399,963 units worth $1,488,111 . The most active insiders traders include Ventures Vii, Llc Vivo Vent..., Ventures Life Sciences 2000... et John J Nicols. On average, Codexis executives and independent directors trade stock every 32 days with the average trade being worth of $153,997. The most recent stock trade was executed by Byron L Dorgan on 15 November 2023, trading 20,000 units of CDXS stock currently worth $42,200.
codexis, inc. is a leading protein engineering company applying innovative technologies to unlock the power of proteins™. our proprietary codeevolver® technology platform enables the rapid development and production of highly optimized proteins, custom-designed for your application. codexis’ revolutionary approach to protein engineering starts with an understanding of the desired performance specifications and optimizes a protein specifically to fit these requirements. you get precisely the protein you need for the job you want it to do. guided by proprietary artificial intelligence software and advanced high-throughput screening systems, codexis is able to efficiently generate and introduce function-driven mutations to rapidly improve a protein for its target application. since 2002, codexis’ in-house biochemists, biologists and bioinformatics experts have worked closely with our clients to advance the technologies for protein optimization and production, enabling breakthrough develop
Codexis executives and other stock owners filed with the SEC include: